United Therapeutics Corp
UTHR
$549.90
+1.02%
United Therapeutics Corp is a biotechnology company specializing in the development and commercialization of therapies for pulmonary arterial hypertension (PAH), a rare and progressive disease. The company is a leader in the PAH space, with a portfolio largely focused on the prostacyclin pathway and anchored by its treprostinil-based products, including its flagship Tyvaso DPI. The current investor narrative is dominated by a significant growth catalyst, as recent positive Phase 3 data for Tyvaso in a new lung disease indication has ignited optimism for substantial market expansion and a forthcoming FDA filing, driving intense debate about the stock's future revenue trajectory.…
UTHR
United Therapeutics Corp
$549.90
Related headlines
Investment Opinion: Should I buy UTHR Today?
Rating & Thesis: Hold. United Therapeutics is a high-quality, profitable company with a transformative catalyst on the horizon, but its current price largely reflects this optimism, leaving limited near-term upside and exposing investors to binary event risk. The bullish analyst sentiment (with 'Buy' and 'Overweight' ratings) and the potential for the Tyvaso expansion support a positive long-term view, but the stock is in a consolidation phase after a major rally.
Supporting Evidence: The stock trades at a trailing PE of 16.17x, which is reasonable for a profitable biotech but offers no clear discount. Revenue growth is stable but modest at 7.38% YoY, and profitability is exceptional with an 86.91% gross margin. The implied upside to the 52-week high of $609.35 is approximately 13.6%, which is not compelling given the associated risks. The company's stellar balance sheet (debt-to-equity of 0) and strong cash flow are supportive factors but are already appreciated by the market.
Risks & Conditions: The two biggest risks are the commercial failure of the Tyvaso expansion and a re-rating of the stock's valuation multiple if growth decelerates. This Hold rating would upgrade to a Buy if the stock corrects meaningfully below $500, providing a better risk/reward entry ahead of the FDA decision, or if Q3/Q4 2026 earnings show an acceleration in core growth. It would downgrade to a Sell if the Tyvaso FDA filing encounters significant delays or if quarterly revenue growth decelerates below 5%. Relative to its own history and the growth implied by its catalyst, the stock is fairly valued to slightly overvalued at current levels.
Sign up to view all
UTHR 12-Month Price Forecast
United Therapeutics presents a classic 'show me' story. The company's exceptional financial health and profitable core business provide a solid floor, but the stock's future trajectory is almost entirely dependent on the successful expansion of Tyvaso. The current price appears to bake in a reasonable probability of success, offering a balanced but unexciting risk/reward profile. The stance is neutral with medium confidence due to the high event risk. An upgrade to bullish would require a pullback to a more attractive entry point (below $500) or clear evidence of accelerating pre-launch demand for the new indication. A downgrade to bearish would be triggered by any regulatory setback for Tyvaso or a breakdown below key technical support near $465.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on United Therapeutics Corp's 12-month outlook, with a consensus price target around $714.87 and implied upside of +30.0% versus the current price.
Average Target
$714.87
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$440 - $715
Analyst target range
Analyst coverage for United Therapeutics is limited, with only 5 analysts providing estimates, indicating it is a mid-cap stock with selective institutional interest. The consensus sentiment appears bullish, as evidenced by recent institutional actions including 'Buy' and 'Overweight' ratings from firms like TD Cowen, UBS, and Cantor Fitzgerald, alongside 'Equal Weight' from Wells Fargo. The average revenue estimate for the period is $6.19 billion, with a wide range from a low of $5.65 billion to a high of $6.89 billion, reflecting significant uncertainty or variance in growth projections. The wide target spread signals high uncertainty around the company's future performance, particularly regarding the commercial success of Tyvaso's potential expansion into new indications, which could justify the high target, while the low target may factor in competitive or execution risks.
Bulls vs Bears: UTHR Investment Factors
The investment debate for United Therapeutics is currently dominated by the bull case, which is strongly supported by a transformative clinical catalyst and an exceptionally strong financial foundation. The most compelling evidence lies in the Phase 3 success of Tyvaso, which could dramatically expand the company's addressable market, combined with a debt-free balance sheet and industry-leading margins. However, the bear case presents a credible counter-argument centered on slowing core growth, high product concentration risk, and the stock's recent technical pullback after a massive rally. The single most important tension in the investment thesis is the binary outcome of the Tyvaso expansion: its successful FDA approval and commercial launch could justify significantly higher valuations, while any regulatory delay or commercial disappointment would expose the company's reliance on a single product and its slowing underlying growth.
Bullish
- Major Growth Catalyst with Tyvaso: Positive Phase 3 data for Tyvaso in a new lung disease indication sets up a major FDA filing and potential market expansion, representing a significant revenue opportunity beyond the core PAH market. This is the primary driver of the stock's 83.94% 1-year surge and the wide analyst revenue target range up to $6.89 billion.
- Exceptional Financial Health: The company has a pristine balance sheet with zero long-term debt (debt-to-equity of 0) and a current ratio of 6.60, indicating ample liquidity. This is complemented by robust free cash flow of $1.04 billion TTM, providing significant financial flexibility to fund growth and weather potential setbacks.
- High Profitability and Pricing Power: United Therapeutics demonstrates exceptional profitability with a gross margin of 86.91% and a net margin of 41.94%. These industry-leading margins reflect the company's pricing power and operational efficiency within its niche, rare disease therapeutic area.
- Valuation Not at Peak Levels: Despite the strong price performance, the trailing PE of 16.17x is well below its recent historical highs (implied by a PS of 27.3x in late 2025). This suggests the stock is not at peak valuation and leaves room for multiple expansion if the Tyvaso catalyst materializes successfully.
Bearish
- Revenue Growth is Slowing: Recent quarterly revenue growth of 7.38% YoY is in the single digits, indicating a maturing core PAH business. The multi-quarter trend shows revenue stabilizing in the high $700 million range, raising questions about the company's ability to accelerate growth without the new Tyvaso indication.
- High Dependence on a Single Product: The company's revenue is heavily concentrated on the Tyvaso franchise, which contributed $464.3 million in the latest segment data. This creates significant execution and regulatory risk, as future growth is now almost entirely tied to the successful approval and commercialization of Tyvaso's expansion.
- Significant Short-Term Pullback: The stock has declined -5.33% over the past month and underperformed the SPY by -6.07%, indicating a pause or consolidation after its powerful rally. This technical weakness suggests momentum may be fading as the market digests the recent news and awaits further catalysts.
- Analyst Uncertainty is High: With only 5 analysts covering the stock, consensus is thin, and the revenue estimate range is wide ($5.65B to $6.89B). This high degree of uncertainty reflects the binary nature of the upcoming Tyvaso catalyst and the difficulty in forecasting its commercial impact.
UTHR Technical Analysis
The stock is in a sustained long-term uptrend, evidenced by a robust 1-year price change of +83.94%, significantly outperforming the broader market. As of the latest close of $536.59, the price is trading at approximately 88% of its 52-week range ($272.12 to $609.35), positioning it near recent highs which reflects strong momentum but also suggests potential overextension. However, recent momentum has diverged, with the stock declining -5.33% over the past month and gaining only +2.35% over the past three months, indicating a significant short-term pullback or consolidation after its powerful rally. This divergence is further highlighted by a negative 1-month relative strength of -6.07 against the SPY, signaling a pause in the uptrend. Key technical levels are clearly defined by the 52-week high of $609.35 as major resistance and the 52-week low of $272.12 as distant support. A breakout above $609.35 would signal a resumption of the powerful bull trend, while a breakdown below recent lows near $464.93 would suggest a deeper correction. The stock's beta of 0.573 indicates it has been significantly less volatile than the overall market, which is notable given its large price moves, suggesting idiosyncratic, company-specific drivers.
Beta
0.57
0.57x market volatility
Max Drawdown
-16.4%
Largest decline past year
52-Week Range
$272-$609
Price range past year
Annual Return
+89.7%
Cumulative gain past year
| Period | UTHR Return | S&P 500 |
|---|---|---|
| 1m | -3.3% | -1.7% |
| 3m | +3.3% | +13.7% |
| 6m | +8.4% | +6.2% |
| 1y | +89.7% | +20.8% |
| ytd | +10.7% | +7.5% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
UTHR Fundamental Analysis
Revenue growth is stable and positive, with the most recent quarterly revenue of $790.2 million representing a 7.38% year-over-year increase. The multi-quarter trend shows consistent revenue in the high $700 million range, indicating steady, single-digit growth, with the Tyvaso franchise being the primary driver, contributing $464.3 million in the latest segment data. The company is highly profitable, with Q4 net income of $364.3 million and an exceptionally strong gross margin of 86.91%. Profitability metrics are robust, with a net margin of 41.94% and an operating margin of 47.67%, reflecting the company's efficient operations and pricing power in its niche therapeutic area. The balance sheet is exceptionally strong, featuring a debt-to-equity ratio of 0, indicating no long-term debt, and a substantial current ratio of 6.60, showcasing ample liquidity. The company generates significant cash flow, with trailing twelve-month free cash flow of $1.04 billion, providing ample internal resources to fund growth initiatives, research, and potential shareholder returns without reliance on external financing.
Quarterly Revenue
$790200000.0B
2025-12
Revenue YoY Growth
+0.07%
YoY Comparison
Gross Margin
+0.86%
Latest Quarter
Free Cash Flow
$1.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is UTHR Overvalued?
Given the company's substantial net income, the primary valuation metric is the Price-to-Earnings (PE) ratio. The trailing PE is 16.17x, while the forward PE is slightly higher at 16.89x; the minimal gap suggests the market expects earnings growth to be roughly in line with current levels, not anticipating a major acceleration or deceleration. Compared to the broader biotechnology sector, a trailing PE in the mid-teens is generally reasonable, though a direct industry average is not provided in the data for a quantified premium/discount analysis. Historically, the stock's own valuation has fluctuated significantly; the current trailing PE of 16.17x sits well below its recent historical highs seen in late 2025 (PE of 27.3x based on PS ratio of 27.3 and net margin of 46.1%), suggesting the stock is not at peak valuation levels despite its strong price performance, potentially leaving room for multiple expansion if growth catalysts materialize.
PE
16.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 9x~66x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
11.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: United Therapeutics faces risks from its high revenue concentration, with the Tyvaso franchise being the primary growth driver. While the company's financials are currently robust, with a 41.94% net margin and $1.04 billion in annual free cash flow, a significant portion of future growth is predicated on the successful launch of Tyvaso in a new indication. Should this launch underperform analyst expectations (the high estimate of $6.89B in revenue), the company's single-digit core growth rate of 7.38% may fail to support its current valuation multiple. Furthermore, the lack of debt, while a strength, also means the company is not leveraging its balance sheet for potentially higher returns.
Market & Competitive Risks: The stock's primary market risk is valuation compression. Although its trailing PE of 16.17x is below its own historical peak, it trades at a premium based on a Price/Sales ratio of 6.78x. If the Tyvaso catalyst fails to materialize into accelerated revenue growth, this premium could contract. Competitive risks in the PAH and broader pulmonary disease space are ongoing, and any new therapeutic entrants could pressure pricing and market share for Tyvaso. The stock's low beta of 0.573 suggests it is somewhat insulated from broad market swings, but it remains exposed to sector-specific sentiment shifts in biotechnology.
Worst-Case Scenario: The most damaging scenario would involve a regulatory setback for the Tyvaso new indication filing, followed by disappointing commercial execution and increased competitive pressure in its core PAH business. This could trigger a re-rating of the stock from a growth story back to a value play, compressing its valuation multiple significantly. A realistic downside could see the stock retreat towards its recent technical support near $464.93 (a -13.4% decline from current price) or even test its 52-week low of $272.12 in an extreme bear case, representing a potential loss of -49.3%. The more probable adverse scenario, aligning with a failed catalyst, would likely see a drawdown in the -20% to -30% range.
FAQ
The key risks are: 1) Clinical/Regulatory Risk: The entire growth thesis hinges on FDA approval and successful launch of Tyvaso in a new indication; any delay or rejection would significantly damage the stock. 2) Product Concentration Risk: Over-reliance on the Tyvaso franchise ($464.3M in latest data) makes the company vulnerable to competitive or pricing pressures in that single product line. 3) Valuation Risk: With the stock trading at 88% of its 52-week range, a failure to break to new highs could lead to a sharp correction as momentum fades. 4) Growth Execution Risk: Core revenue growth has slowed to 7.38% YoY; the company must demonstrate it can re-accelerate growth even with the new indication.
The 12-month forecast for UTHR is scenario-dependent. The base case (50% probability) sees the stock trading between $540 and $600 as the Tyvaso catalyst progresses steadily. The bull case (30% probability), involving a strong FDA approval and launch, targets $609 to $675. The bear case (20% probability), involving regulatory or commercial setbacks, sees a decline to $465-$520. The most likely scenario is the base case, which assumes a standard regulatory process and steady execution, but the wide range of analyst revenue estimates ($5.65B to $6.89B) underscores the high uncertainty.
UTHR appears fairly valued to slightly overvalued based on its current fundamentals. Its trailing PE of 16.17x is reasonable for a profitable biotech but is not a discount. The Price/Sales ratio of 6.78x suggests the market is paying a premium for future growth, which is contingent on Tyvaso's expansion. Compared to its own historical peak valuation (implied by a PS of 27.3x), it is not expensive, but this historical high was likely driven by similar catalyst hopes. The valuation implies the market expects successful commercialization of the new Tyvaso indication to drive accelerated growth.
UTHR is a good stock for a specific type of investor. For those seeking a high-quality, debt-free company with a potentially transformative catalyst, it holds appeal. However, at its current price near $536.59, much of the optimism is already reflected, offering only ~13.6% upside to its all-time high. It is a good buy for patient, risk-tolerant investors who believe strongly in the Tyvaso expansion and are willing to hold through FDA review volatility. Conservative investors may find better entry points on pullbacks below $500.
UTHR is more suitable for a medium-to-long-term investment horizon (12-24 months minimum). The key value driver is the commercial rollout of a new drug indication, which will unfold over quarters and years, not days or weeks. The stock's low beta of 0.573 suggests it is not ideal for short-term trading based on market momentum. Furthermore, it pays no dividend, eliminating income as a short-term rationale. Investors should be prepared to hold through the volatility of the FDA review process and the initial launch phase to fully realize the potential of the investment thesis.